ADIRF

Across TCGA pan-cancer cohorts, ADIRF Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADIRF data layer compared with 9 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ADIRF Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADIRF expression acts as an unfavorable survival marker.

COAD, SARC, and LIHC are the cancer types where ADIRF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.111	0.871	<.001	18	view →
SARC	OS	Median	All	0.161	0.747	<.001	12	view →
LIHC	OS	Median	All	0.061	0.783	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADIRF–COAD (OS)

Open the COAD breakdown →